Risk factors for pneumonitis in solid tumors treated with anti-programmed death-1 therapy: A case-control study.

被引：1
|
作者：
Cui, Pengfei
Liu, Zhefeng
Wang, Guoqiang
Ma, Junxun
Qian, Yuanyu
Zhang, Fan
Han, Chun
Long, Yaping
Li, Ye
Zheng, Xuan
Sun, Danyang
Zhang, Jing
Cai, Shangli
Jiao, Shun Chang
Hu, Yi
机构：
[1] Chinese Peoples Liberat Army Gen Hosp, Dept Med Oncol 1, Beijing, Peoples R China
[2] Gen Hosp PLA, Beijing, Peoples R China
[3] 3D Med Inc, Dept Med, Shanghai, Peoples R China
[4] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
[5] Chinese Peoples Liberat Army Gen Hosp, Dept Oncol, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e15132
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15132
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Clinical Outcomes of Anti-programmed Death-1 Antibody–Related Pneumonitis in Patients with Non-Small Cell Lung Cancer
    Takafumi Koyauchi
    Naoki Inui
    Masato Karayama
    Yoshihiro Kitahara
    Sho Takuma
    Yusuke Amano
    Hideki Yasui
    Hironao Hozumi
    Yuzo Suzuki
    Kazuki Furuhashi
    Tomoyuki Fujisawa
    Noriyuki Enomoto
    Yutaro Nakamura
    Mitsuru Niwa
    Nao Inami
    Yasuhiro Ito
    Hideki Kusagaya
    Shun Matsuura
    Yusuke Kaida
    Tomohiro Uto
    Dai Hashimoto
    Takashi Matsui
    Kazuhiro Asada
    Hiroyuki Matsuda
    Masato Fujii
    Mikio Toyoshima
    Takafumi Suda
    SN Comprehensive Clinical Medicine, 2020, 2 (5) : 570 - 578
  • [42] A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors
    Desai, Jayesh
    Markman, Ben
    Sandhu, Shahneen Kaur
    Gan, Hui Kong
    Friedlander, Michael
    Tran, Ben
    Meniawy, Tarek
    Boolell, Vishal
    Colyer, Duncan
    Norris, Christie
    Ameratunga, Malaka
    Yang, Jason
    Li, Kang
    Wang, Lai
    Luo, Lusong
    Qin, Zhen
    Millward, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] Prognostic role of platelet to lymphocyte and lymphocyte to monocyte ratios in advanced melanoma treated with anti-programmed death-1
    Minowa, Tomoyuki
    Kato, Junji
    Hida, Tokimasa
    Horimoto, Kohei
    Sato, Sayuri
    Sawada, Masahide
    Uhara, Hisashi
    EUROPEAN JOURNAL OF DERMATOLOGY, 2018, 28 (05) : 705 - 707
  • [44] Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials
    Nie, Run-Cong
    Chen, Fo-Ping
    Yuan, Shu-Qiang
    Luo, Ying-Shan
    Chen, Shi
    Chen, Yong-Ming
    Chen, Xiao-Jiang
    Chen, Ying-Bo
    Li, Yuan-Fang
    Zhou, Zhi-Wei
    EUROPEAN JOURNAL OF CANCER, 2019, 106 : 1 - 11
  • [45] Immunological features of a lung cancer patient achieving an objective response with anti-programmed death-1 blockade therapy
    Kamata, Toshiko
    Yoshida, Shigetoshi
    Takami, Mariko
    Ihara, Fumie
    Yoshizawa, Hiroko
    Toyoda, Takahide
    Takeshita, Yuichiro
    Nobuyama, Seiichi
    Kanetsuna, Yukiko
    Sato, Tetsuo
    Yoshino, Ichiro
    Motohashi, Shinichiro
    CANCER SCIENCE, 2020, 111 (01) : 288 - 296
  • [46] Effective anti-programmed death-1 therapy in a SUFU-mutated patient with Gorlin-Goltz syndrome
    Moreira, A.
    Kirchberger, M. C.
    Toussaint, F.
    Erdmann, M.
    Schuler, G.
    Heinzerling, L.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (03) : 747 - 749
  • [47] Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study
    Norio Okada
    Shintaro Iwama
    Takayuki Okuji
    Tomoko Kobayashi
    Yoshinori Yasuda
    Eri Wada
    Takeshi Onoue
    Motomitsu Goto
    Mariko Sugiyama
    Taku Tsunekawa
    Hiroshi Takagi
    Daisuke Hagiwara
    Yoshihiro Ito
    Hidetaka Suga
    Ryoichi Banno
    Tetsunari Hase
    Masahiro Morise
    Mitsuro Kanda
    Kenji Yokota
    Naozumi Hashimoto
    Masahiko Ando
    Yasushi Fujimoto
    Masato Nagino
    Yasuhiro Kodera
    Mitsuhiro Fujishiro
    Hideharu Hibi
    Michihiko Sone
    Hitoshi Kiyoi
    Momokazu Gotoh
    Yuichi Ando
    Masashi Akiyama
    Yoshinori Hasegawa
    Hiroshi Arima
    British Journal of Cancer, 2020, 122 : 771 - 777
  • [48] Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study
    Okada, Norio
    Iwama, Shintaro
    Okuji, Takayuki
    Kobayashi, Tomoko
    Yasuda, Yoshinori
    Wada, Eri
    Onoue, Takeshi
    Goto, Motomitsu
    Sugiyama, Mariko
    Tsunekawa, Taku
    Takagi, Hiroshi
    Hagiwara, Daisuke
    Ito, Yoshihiro
    Suga, Hidetaka
    Banno, Ryoichi
    Hase, Tetsunari
    Morise, Masahiro
    Kanda, Mitsuro
    Yokota, Kenji
    Hashimoto, Naozumi
    Ando, Masahiko
    Fujimoto, Yasushi
    Nagino, Masato
    Kodera, Yasuhiro
    Fujishiro, Mitsuhiro
    Hibi, Hideharu
    Sone, Michihiko
    Kiyoi, Hitoshi
    Gotoh, Momokazu
    Ando, Yuichi
    Akiyama, Masashi
    Hasegawa, Yoshinori
    Arima, Hiroshi
    BRITISH JOURNAL OF CANCER, 2020, 122 (06) : 771 - 777
  • [49] Smoking-Related Outcomes of Advanced Stage Lung Cancer Treated with Anti-Programmed Cell Death-1 (PD-1) Therapy: A Single Institution Study
    Hafiz, M.
    Naqash, A. R.
    Stroud, C. R. G.
    Bowling, M.
    Walker, P. R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1568 - S1569
  • [50] Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy
    Tang, Kimberly
    Seo, Jayhyun
    Tiu, Bruce C.
    Le, Thomas K.
    Pahalyants, Vartan
    Raval, Neel S.
    Ugwu-Dike, Pearl O.
    Zubiri, Leyre
    Naranbhai, Vivek
    Carrington, Mary
    Gusev, Alexander
    Reynolds, Kerry L.
    LeBoeuf, Nicole R.
    Asgari, Maryam M.
    Kwatra, Shawn G.
    Semenov, Yevgeniy R.
    JAMA DERMATOLOGY, 2022, 158 (02) : 189 - 193
12345